ES2154693T3 - Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias. - Google Patents

Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.

Info

Publication number
ES2154693T3
ES2154693T3 ES95107299T ES95107299T ES2154693T3 ES 2154693 T3 ES2154693 T3 ES 2154693T3 ES 95107299 T ES95107299 T ES 95107299T ES 95107299 T ES95107299 T ES 95107299T ES 2154693 T3 ES2154693 T3 ES 2154693T3
Authority
ES
Spain
Prior art keywords
substances
necrosis
tumors
combination
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95107299T
Other languages
English (en)
Inventor
Klaus Dr Bosslet
Jorg Dr Czech
Dieter Dr Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2154693T3 publication Critical patent/ES2154693T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMBINACION DE SUSTANCIAS INDUCIDORAS DE NECROSIS (COMPONENTE I), ES DECIR ENDOTHEL DE PERFILACION, EN TUMORES O TEJIDOS DE INFLAMACION CON OTRAS SUSTANCIAS NO TOXICAS ("PRODRUGS", COMPONENTE II). LA ENZIMA LIBERADA A TRAVES DEL PROCESO NECROTICO DESDOBLA "PRODRUG" NO TOXICO EN EL "DRUG" TOXICO, QUE CONDUCE A CELULAS MUERTAS TUMORALES MASIVAS O AL RETORNO DE INFLAMACION.
ES95107299T 1994-05-20 1995-05-13 Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias. Expired - Lifetime ES2154693T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4417865A DE4417865A1 (de) 1994-05-20 1994-05-20 Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Publications (1)

Publication Number Publication Date
ES2154693T3 true ES2154693T3 (es) 2001-04-16

Family

ID=6518684

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95107299T Expired - Lifetime ES2154693T3 (es) 1994-05-20 1995-05-13 Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.

Country Status (14)

Country Link
US (1) US5710134A (es)
EP (1) EP0696456B1 (es)
JP (1) JP4576005B2 (es)
KR (1) KR100386492B1 (es)
AT (1) ATE199645T1 (es)
AU (1) AU2015195A (es)
CA (1) CA2149818C (es)
DE (2) DE4417865A1 (es)
DK (1) DK0696456T3 (es)
ES (1) ES2154693T3 (es)
GR (1) GR3035593T3 (es)
NZ (1) NZ272150A (es)
PT (1) PT696456E (es)
ZA (1) ZA954099B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
ATE316799T1 (de) * 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US10973397B2 (en) 1999-03-01 2021-04-13 West View Research, Llc Computerized information collection and processing apparatus
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
EP1171118A2 (en) * 1999-04-09 2002-01-16 Jessie L.S. Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
AU4243201A (en) * 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
ES2312478T3 (es) * 2000-09-07 2009-03-01 Bayer Schering Pharma Aktiengesellschaft Receptor del dominio edb de fibronectina (ii).
EP1515707A4 (en) * 2001-06-20 2005-10-19 Imclone Systems Inc METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS AND OTHER INFLAMMATORY DISEASES
CA2454251A1 (en) * 2001-08-10 2003-02-20 Imclone Systems Incorporated Isolation and mobilization of stem cells expressing vegfr-1
EP2269656B1 (en) 2002-07-15 2014-08-20 Board Of Regents, The University Of Texas Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer
KR20170102377A (ko) 2004-01-22 2017-09-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
CN101031287A (zh) * 2004-03-02 2007-09-05 麻省理工学院 纳米细胞药物递送系统
EP1750172B1 (en) * 2004-05-26 2013-04-24 Nikon Corporation Wavelength converting optical system
JP4864900B2 (ja) 2004-11-18 2012-02-01 イムクローン・リミテッド・ライアビリティ・カンパニー 血管内皮成長因子受容体−ｉに対する抗体
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) * 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
WO1992017151A2 (en) * 1991-03-27 1992-10-15 Lankenau Medical Research Center Method of administering drugs through modification of epithelial tight junctions by tumor necrosis factor
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
DK0696456T3 (da) 2001-06-25
ZA954099B (en) 1996-01-19
EP0696456A3 (de) 1998-10-28
DE59509088D1 (de) 2001-04-19
KR950031106A (ko) 1995-12-18
PT696456E (pt) 2001-07-31
EP0696456B1 (de) 2001-03-14
ATE199645T1 (de) 2001-03-15
JP4576005B2 (ja) 2010-11-04
DE4417865A1 (de) 1995-11-23
AU2015195A (en) 1995-11-30
JPH07316074A (ja) 1995-12-05
NZ272150A (en) 1997-04-24
GR3035593T3 (en) 2001-06-29
EP0696456A2 (de) 1996-02-14
CA2149818C (en) 2010-03-23
KR100386492B1 (ko) 2003-08-14
US5710134A (en) 1998-01-20
CA2149818A1 (en) 1995-11-21

Similar Documents

Publication Publication Date Title
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
DE69910560D1 (de) Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga
ATE417604T1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
ATE324119T1 (de) Verwendung von saccharid-konjugaten
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
ES2192839T3 (es) Timosina beta 4 oxidada.
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
ES2071995T3 (es) Composicion para la activacion de macrofagia.
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
PT1001756E (pt) Composicoes com actividade sinergetica para o combate selectivo de tecido tumoral
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
BR9612549A (pt) Método para tratamento de agressão excessiva

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 696456

Country of ref document: ES